Does it Pay to Use Pathways?
As healthcare providers implement clinical pathway programs, they will face a variety of challenges and opportunities - especially when it comes to measuring patients' adherence.Seema Sonnad, PhD, associate editor for The American Journal of Managed Care, and director of Health Services Research at The Value Institute at Christiana Care Health System, leads a panel discussion that focuses on clinical pathway adherence. She is joined by panelists Jennifer Malin, MD, PhD, medical director, Oncology for Care Management, WellPoint, Chadi Nabhan, MD, FACP, associate professor of medicine, section of hematology and oncology, medical director, clinical outpatient cancer center, the University of Chicago, Dr. I.W. Tischler, national medical director, oncology, Cigna, and Peter Paul Yu, MD, FASCO, 2014-2015 ASCO president, medical oncologist and hematologist, director of cancer research at Palo Alto Medical Foundation.
Seema Sonnad, PhD, associate editor for The American Journal of Managed Care, and director of Health Services Research at The Value Institute at Christiana Care Health System, led a panel discussion that focused on oncology clinical pathway adherence.
The panelists discussed and shared examples of how payers and providers are collaborating to develop pathway guidelines.
Dr Yu said that it is crucial for providers’ voices to be heard in pathway development.
Dr Sonnad asked panelists about the participants on payer panels who determine the cost-effectiveness of pathways.
In this segment, panelists discussed the various tools that are used to measure pathway adherence.
The panelists further explore feedback and its role in pathway adherence.
Dr Sonnad inquired how replacing brand drugs with generic equivalents can affect pathway adherence. She also asked panelist to discuss the differences between early-stage and late-stage disease regimens, as well as the degree of flexibility there is in regimen design.